Aurinia Pharmaceuticals Inc (AUPH)

[biotech_researcher]

Ariad had two drugs. one Ponatinib that was FDA approved before Takeda bought them out, and the drug for NSCLC Brignatinib that was in a ph3 trial and was approved shortly after Takeda bought the company. That second drug is what swayed Takeda. Unfortunately, Aurinia is just one trick pony. That reduces the desire for buyout. You only have one shot on goal.